VQI Midwest Vascular Collaborative Region
November 5th, 2020
6:00 pm – 8:00 pm
Remote

Participation Award Credit – only available if attendee signed in correctly!

---

Agenda

- Regional Data Review
- Regional QI Proposal
- National VQI Update
- AQC Update
- VQC Update
- RAC Update
- Governing Council Update
- Case Presentation
- Open Discussion/Next Meeting/Meeting Evaluation – EC Recap

Disclosures: Relevant to the content of this educational activity the presenters have no conflict(s) with commercial interest companies to disclose.

---

Welcome and introductions: Gary Lemmon, MD

- Dr. Lemmon stepping down as Regional Director.
- Dr. Xenos assuming directorship of Midwest Vascular Collaborative
- Continuous growth within our region. Around 35 centers participate in the VQI Midwest Vascular Collaborative region.

---

Regional Data Review: Gary Lemmon, MD & Eleftherios Xenos, MD

Dashboard Comments:
- Note Regarding metrics in dashboard: for a region to show in dashboard, it must have >=3 centers (each one with >10 eligible cases in it). There are current discussion in SVS regarding on how to continue to show comparative reports due to its low volume (and rules of current/prior
reports). Discussion on future report to include longer timeframes as a possible way to bypass the problem.

- **Any outlier center can reach out to VQI SVS PSO for assistance in improving their metrics and/or contact Midwest Vascular Collaborative region to discuss how other centers have worked on improving their metrics.**

- **Procedure volumes** in most centers are a little higher in the region than most centers in the nation (50 percentile in the region is 119 vs 88 nationwide).

- **Physician Specialties:** our region has a higher representation of interventional radiologist and interventional cardiologist compared to nationwide. Around 42% cases in our region are done by vascular surgery, 24% by radiology, 20% by cardiology and 14% by other specialties (General surgery, CT surgery, neurosurgery, etc); vs nationwide which is 45%, 15%, 15% and 25% correspondingly.

- **Long Term Follow Up:** Our region is doing a fantastic job for Long Term Follow-Up (LTFU). The aggregate LTFU is at 75% (vs 68% nationwide). There is a wide variation on this metric is around 29-87% nationwide. The follow up rate decreased slightly from las year, yet is still better than national average. **Our region shows excellence and dedication to our patients by being in “top 2 regions” with compliance on LTFU!!!** Note: This is a VQI Quality Improvement (QI) metric.

- **Discharge medication** compliance in our region is 87% (vs 85% nationwide). Most centers in our region are above the 70% compliance for dc meds.

- **Carotid Stent:** This year VQI has broken down Carotid Artery Stenting (CAS) into Transcarotid (TCAR) approach and Transfemoral (TFEM) approach, also broken it down into asymptomatic and symptomatic cases.
  - Our region does not have enough centers performing TFEM CAS (Asymptomatic and Symptomatic).
  - As for **Asymptomatic TCAR**, our region is doing really good in **stroke and death** outcomes with a half of the rate in our region compared to benchmarks (region is 0.5% rate vs 1% nationwide).
  - For symptomatic TCAR, we do not have enough centers with eligible cases.

- **Carotid Endarterectomy:** This year VQI has broken down Carotid Endarterectomy (CEA) into asymptomatic and symptomatic cases.
  - For Asymptomatic CEA:
    - **Stroke and death rate** are the same in region as nationwide (0.9% for regional and national). Only 2 centers in our region have a rate of more than 0%.
    - **“Post-op LOS > 1day”** is lower than benchmarks.
  - For Symptomatic CEA:
    - **Stroke and death rate** is slightly higher than benchmarks (region 2.3% vs nation 1.7%) with an expected rate of 1.7% yet p-value of 0.42. Only 1 center in the region has a rate higher than 0%.
    - **“Post-op LOS > 1day”** is on par with national benchmarks (regional 42% vs 43% nationwide). Most centers in our region have a rate lower than expected, with only 2 centers higher than expected.

- **EVAR Outcomes:**
  - **Post-Op LOS > 2days:** Our region has always been in the top 5 regions in the country on discharging patients in less than 2 days (region 12% vs 14% nationwide; expected 13%).
All of our centers are at or below our expected rate. This is important as LOS>2 days can be a proxy for worse outcomes and for reimbursement reasons as well.

- **Sac diameter reporting at LTFU**: is better than benchmarks (region 65% vs 59% nationwide) but still has room to improve. There is a wide variation on this metric is around 22-89% nationwide. This is a VQI National QI metric. Discussion among members regarding barriers from some centers for not improving include:
  - Patients lost to follow up
  - Imaging not done
  - Imaging reports not done in current center
  - Aortic sac diameter not measured in imaging report.

  Centers with good compliance stated that improvement was a result of having the manpower to call patient and getting to come back for follow up and ensuring their test is done at it. Other centers stated that they requested radiology department to ensure aortic diameter was included in the imaging report. Reminded that Ultrasound is acceptable for testing and that diameter can be measured with it. When diameter is not included in the report, it can be measured by physician and added to the LTFU notes. Providing periodic reports to physicians, assisted in awareness of missing.

- **Sac Size Guidelines**: Our region adhere less to sac size guidelines than benchmarks (region 70% vs 73% nationwide). We are in the lower percentile compared to other regions on sac diameter guidelines adherence. Members provided feedback to SVS/VQI on importance of adding saccular vs fusiform aneurysm and growth of aneurysm to ensure accuracy with this metric.

• **TEVAR Outcomes**: Sac Diameter reporting at LTFU in our region is slightly lower than benchmarks (region 47% vs 57% nationwide). Refer to notes of EVAR Sac diameter at LTFU for discussion.

• **Open AAA (OAAA) outcomes**: There are 7 centers participating in OAAA but only 1 center has more than 10 cases to report in the timeframe of this report. There are current discussion in SVS regarding on how to continue to show comparative reports for open AAA care due to its low volume (and rules of current/prior reports). Other regions have higher participation due to strong belief in offering OAAA on patients that falls out of IFU outside (especially in suboptimal anatomy).
  - **In Hospital Mortality**: National benchmarks show mortality in the 4.2%, with a breakdown of cases based on their proximal clamp location: Infrarenal clamp at 2.9% mortality, and suprarenal clamp at 5.7% mortality.
  - **Cell Saver Guideline**: National benchmarks show a 93% compliance with SVS guidelines.
  - **SVS Iliac Inflow Guideline**: National benchmarks show a 99% compliance with SVS guidelines.

• **PVI Outcomes**: ABI/Toe pressure compliance is lower than benchmarks (our region is 71% vs 75% nationwide). Most centers in our region are above 50% compliance. There is plenty room to improve this metric.

• **Infrainguinal Outcomes**: Major complication rates in our region are better than benchmarks (regional 2.9% vs 4.1% nationwide). Our region have consistently outperformed in this outcome.

• **Suprainguinal Outcomes**: Major complication we do not have enough centers with eligible cases. Nationwide benchmarks showed 5.2% rate for major complications. There are current
discussion in SVS regarding on how to continue to show comparative reports due to its low volume (and rules of current/prior reports).

- **Lower extremity Amputations:** our region has < 3 centers participating in this module. There are current discussion in SVS regarding on how to continue to show comparative reports due to its low volume (and rules of current/prior reports). **Post-Operative Complication Rates** in the nation is 12%.

- **Varicose Veins:** our region has < 3 centers participating in this module.

- **AV Access Outcomes:** Our region is doing well on **Primary AVF vs Graft** compared to benchmarks (region 87% vs 82%). 4 Centers in our region participates in this registry and all are above 80% compliance with it.

- **IVC Filter:** Our region has very few IVC Filter participation. **Filter Retrieval Reporting (or attempt to remove)** nationwide is really low at 23%. Noted that 72% of these cases had no LTFU record, and 4% were not clinically indicated to remove. Members discuss possibility of discussion among other societies (i.e. Radiology) to see how to improve this metric.

---

**Regional Improvement Projects: Xenos, MD**

---

- **Sac diameter reporting at LTFU – was chosen by the members as a collective regional improvement project.**
  - Members suggested to SVS representative of having this measurement as 2 variables:
    - A. from the total of cases done
    - B. from the total of cases with a LTFU
  - Cheryl Jackson cjackson@svspso.org provides a platform for process improvement webinars and calls that addresses process improvement projects within VQI community.

---

**National VQI Update: Jim Wadzinski, SVS PSO**

---

**Vascular Medicine Consult Registry**

**Inclusion Criteria:**
This registry only includes New Outpatient Consults who are being treated medically for:
- Lower Extremity peripheral arterial disease due to atherosclerosis
- Atherosclerotic carotid artery occlusive disease
- Abdominal aortic aneurysm

**Exclusion Criteria:**
Evaluation/diagnosis of pseudo or neurogenic claudication, peripheral arterial disease due to trauma, popliteal entrapment, medial adventious cystic disease, chronic compartment syndrome
Carotid disease due to dissection, infection, aneurysm, tumor, isolated common carotid lesion not thought to involve the bifurcation, disease of the carotid bifurcation due solely to vasculitis, and Moyamoya disease, and fibromuscular dysplasia
Isolated aortic dissection without aneurysm
Thoracic, thoraco-abdominal, and mycotic aneurysms
Vascular Medicine Consult Registry

Data Collection:
Registry to focus on non-operative medical management of these conditions
Medication details and dosages, along with lifestyle modifications and counseling will be the emphasis of this registry

Opportunities
Identify patterns/variation of treatment and pre-intervention management
Identify QI initiatives
Opportunities in comparative effectiveness research
First site signed and entering data! Many more in the contracting phase!
Recorded webinars: https://www.vqi.org/vascular-medicine-consult-registry-webinar-recordings-available/
For more information please contact: VQI@M2S.com

VQI OnLine Highlights:
- VQI OnLine hosted 12 sessions over 6 weeks
- Attendance ranged from 300 – 125 live users
- PSO thanks all the Speakers and Moderators
- Feedback has largely been positive.
- Need a better registration and invite process
- Will incorporate virtual sessions even as we return to a live event
- Replays can be found on the VQI Members Only website.

VQI OnLine:
After the successful completion of our first VQI ONLINE event series, we have posted the video content on the Members Only area
If you wish to view any of the video sessions, please log in to the VQI Members Only area on the website. (If you do not have credentials for Members Only, please contact Nancy Heatley to set up your access. This is only available for registered VQI members.)
VQI Members Only – https://www.vqi.org/members-login/
Full recordings of each event are available at no cost to VQI members through Members Only. Contact Nancy Heatley Nheatley@svspso.org if you need assistance!

ACC, SVS Join Forces on Single Vascular Registry
The American College of Cardiology and Society for Vascular Surgery are collaborating on a single vascular registry to harness the strengths of both organizations in improving care and outcomes of patients with vascular disease.

https://www.vqi.org/acc-svs-join-forces-on-single-vascular-registry/

**Member discussion:** This will not affect current VQI PVI participants. It will only increase centers available to compare (potentially). There won’t be a migration of data from ACC to VQI. ACC will not be accepting new recruiting centers in the retired module (or new data entered in 2021). Current ACC participating centers will still have access to their data within ACC until 2022.

**COVID-19 Variables:** See slides

**PAD Patient Reported Outcomes (PROs)**

**My Peripheral Arterial Disease: a VQI Pilot of Patient Reported Outcomes for PAD**

The Society for Vascular Surgery Vascular Quality Initiative is seeking practices to participate in *My PAD*, a pilot program for the collection of patient reported outcomes (PRO) on patients undergoing endovascular treatment for peripheral arterial disease (PAD).

The VQI recognizes that traditional outcomes such as patency and reintervention may not fully capture the quality of care or the experience of PAD patients. There is a long overdue need to learn and measure the patient’s perspective.

Must be in the PVI registry and have greater than 80% follow up!

**PAD Patient Reported Outcomes (PROs)**

**Highlights**
- Outpatient peripheral vascular interventions (PVI) for claudication or chronic limb threatening ischemia
- Collect VascuQoL-6 and EuroQoL 5D-5L (estimated completion time 10-15 minutes)
- Collection at three time points: pre-procedure, one month and one year postoperatively
- PRO data entry options include paper forms, computer, tablet and smart phone
- Educational materials for direct from patient data entry
- PRO feedback to participating physicians

**Reporting Highlights and Questions:**

Changes to Perioperative Dashboards

New On-line LTFU reports

Suggestions for “other reports”?

Perioperative

Dashboard Remodel

**Overall Modifications**

Change explanation language- confusing

*Note also that percentages are computed only among cases with non-missing data for each outcome, so it is possible to have rates for some outcomes but “No cases” for others.*

*Better to say?: Only cases with complete data have been analyzed.*

Reorder sequence

Combine CAS and CEA under “All carotid interventions”- give % of type
All Carotid; then all Aortic (TEVAR/EVAR/OAAA/Supra); then all LE (PVI/LEB/Amp); then all Vein (VV/IVC/AVF); then Medical
Eliminate null entry of registry data
Inefficient and visual fatigue- leave blank and provide no entry; should not require major reprogramming
Develop common metric for complications
Return to OR (RTOR) should be common to all with ‘BTR’: bleeding/thrombosis/revision and then use registry specific complications in separate row or with BTR
Provide 0 year and 3 year comparators
Since Dashboard is quarterly, a rapid look at 1Y and 3Y trend data will be very useful and can be provided via linkage
Include Category under each registry of excluded ‘N’s
Reorganize sequence: Carotid→Aortic→LE→Vein→Medical
Rolling quarter concept to allow for statistical merit on low volume procedures such as OAAA, etc. to achieve N > ~15. This would also be carried over to LTFU regional reports comparison
Add LTFU metric to category dashboard→Hyperlink option
Replace 25th /50th/75th percentile with whiskerplot: 90-10%tile which shows median of VQI and arrow locating center level %tile

Carotid
Combine into all carotid interventions for total of procedures in center
Asymptomatic definition changed to 180 days
Breakout into % CAS vs CEA as well as %TCAR vs TFCAS
Under each category above: % Age >/= 80 and % CMS High Risk Criteria
MACE reported separated for Total CAS (TCAR + TFCAS) and CEA
Contralat/Ipsi CVA reported for each procedure type
List BTR separately from Cranial Nerve Injury
% Protamine reversal included in CEA report
Continue with ‘Case data’; ‘DC meds’; ‘Discharge’; ‘IV meds for BP’ and Dysrhythmia treatment

Combined totals used when statistics do not support separating outcomes and in ‘Home’ disposition
Homeless and other hospital eliminated from Disposition

Carotid Stenting and Endarterectomy

Member Discussion: Members suggested to SVS to have these reports be individualized by physician to as a best practice report.
**Member Discussion:** Indiana University Health participated in the pilot of this report. Stated that this report will assist in Sac Diameter at LTFU quality improvement project that our region will embark into.

**Regional Bylaw Changes**

**Quorum:**
All voting for nominations and election of officers will be conducted electronically, even during in-person regional meetings. In order to conduct business, a quorum of the regional Executive Committee (EC) is considered a majority vote of all regional members of the EC that participate in the voting process. Centers are eligible to vote as of the date of the signed contract. No waiting period is required. The regional EC is entitled to one vote per center.

An email notification to the region will be forwarded one week prior to the opening of officer nominations. A region will be permitted a collection period of one week to nominate individuals for the respective office and subsequently the regional EC will be given three weeks to vote for their member of choice.

A regional EC member may designate a proxy for the purposes of voting provided that the VQI is notified in writing, by replying to the voting communication, prior to the end of the voting period. For voting that takes place without SVS PSO involvement, the Regional Medical Director will manage and conduct the voting process in accordance with the regional Bylaws’ rules of voting, meeting a quorum. The Regional Medical Director will give prior notification to the regional EC, by means of an agenda, if a vote will be conducted during an upcoming EC meeting or regional meeting.

**Regional Bylaw Changes**

**Associate Medical Director:**
The Regional Associate Medical Director (AMD) is a VQI participating physician that will be nominated by the regional Executive Committee (EC) with a final vote based on the regional bylaw policies. This position will report directly to the Regional Medical Director. The Regional AMD will support the Regional Medical Director in managing the region with the application of regional guidelines. Tasks include, but are not limited to, assisting with agenda preparation, budgeting, regional meeting planning and the overall operations of the region. This role is a three-year renewable term, with an automatic succession into the Regional Medical Director’s role unless the SVS PSO receives written objection(s) from member(s) of the regional EC. A final vote of the regional EC is required to sanction the transition from Regional AMD to Regional Medical Director.

**Regional Bylaw Changes**

**Medical Director Qualifications:**
The Medical Director is a VQI participating physician selected for a three-year renewable term by a majority vote, as defined in the regional Bylaws, of the Executive Committee (EC). The Regional Medical Director chairs the EC, prepares the agenda for meetings, prepares an annual budget and is responsible for the overall operations of the region between meetings of the EC. The Regional Medical Director will represent the region on the SVS PSO National Governing Council, unless the EC decides to elect someone else in the region.

**CME/CE CREDIT FOR REGIONAL MEETINGS**
Start on FALL 2020
Participation Award Changes
We are aware that COVID-19 placed a significant strain on staff and resources
Formal announcement sent out April 9, 2020
Personnel may have been reassigned making the performance of usual operations difficult if not impossible
Many patients have had their follow-up office visits delayed. This may result in patients being seen outside of the prescribed time period (9-21 months) which is beyond anyone’s control.
Workflow disruptions may have caused delays in data entry and follow-up
The Participation Committee will assess the 2020 Participation Award criteria to assure that temporary workflow disruptions will not have a negative impact on participation awards.
Updates will be provided via December QI webinar, newsletter, and email blast.

Quality Improvement Update
Fall 2020
Quality Improvement Webinars: (all webinars are archived in “Members Only” website)
  ▪ 2020 Quarterly Webinars
    ▪ March 2020
      ▪ “Starting a QI project”
    ▪ June 2020
      ▪ Deferred for Online VQI
    ▪ September 2020
      ▪ Featuring Northern California Vascular Study Group and their processes for two regional projects
    ▪ November/December 2020
      ▪ 2020 Participation Award Information, 2021 Changes and Wrapping up a QI Project

2020 Quality Improvement
Fourteen charters submitted
*LTFU – 5
D/C Medications – 4
Clinical – 2 (LOS – EVAR, LE)
**Documentation – 1 (AAA size compliance)
*2 regions finalizing details for LTFU QI project
** Multi-regional project - finalizing details for AAA size compliance QI project
Focused phone calls are well attended

Recap of 2019/2020 QI Projects
Putting VQI Data into Action
See what your colleagues are doing with QI
Twenty-eight poster abstracts were submitted and accepted for presentation at the 2020 VQI Annual meeting that was scheduled for Toronto
Five abstracts were featured in the Online QI session
Seven abstracts were featured in the Online RAC session
Great feedback received for all presentations!

Thanks to all who presented and attended the Online VQI sessions!
Quality Improvement Details: Charter Information

**Charters**
- Charter participants become part of focused group calls
- Interactive discussion sharing barriers and successes
- Sharing of charters
- Networking
- Checking in – where are you in the process
- Celebrating success

One on one calls, if requested

**Newsletters**
- The VQI News
  - Distributed every other month
  - Provides updates on regulatory issues, technical updates, and crossover news from the SVS and SVN
- VQI Quality Improvement Newsletter
  - Distributed every other month
  - Focusing on QI processes, tools, and definitions

**National QI project details**
Submit Project Charters and supporting documentation for presentations and posters to QI@SVSPSO.ORG or cjackson@svspso.org.
Visit the VQI Members Only Website for sample charters, webinars, and presentations on VQI Quality Improvement Projects. www.vqi.org

---

**AQC Update – Bradley Thomas, MD**

Randy DeMartino, MD (Mayo Clinic Rochester) is the new Chair of the AQC

**AQC Update:**
Current projects:
Common variable help text updates
OAAA registry revisions
SVS guidelines collaboration
COVID variables
Patient reported outcome variables

---

**VQC Update – Ziad Fayad, MD**

Marc Passman, MD (UAB) new chair of the VQC taking over for Jose Almeida, MD

1-3 year goals
Dedicated podium time for VQI at AVF
Update Varicose Vein and IVC quarterly interoperative dashboards
Create Venous Stent dashboard
Work on LTFU dashboards for all 3 venous procedures
Continue work C2 disease and appropriateness of care
Continue work with United Healthcare
IVC retrieval rate is 30% nationally, need to make this a national quality initiative
Create COPI (Center Opportunity for Process Improvement) reports for venous registries

RAC Update – Raghu Motaganahalli, MD

Nicholas Osborne, MD (Univ of Michigan) FIRST chair of the new Venous RAC
Arterial RAC and Venous RAC alternate months for submissions:

Proposal Process:
1. Review list of projects approved to avoid duplication
   https://www.vqi.org/data-analysis/rac-approved-project-search/
2. Submit proposal on line:
   http://abstracts123.com/svs1/meetinglogin

GC Update – Mike Dalsing, MD

Appointments of Vice-Chairs to the VQC and VRAC
Dr. Mark Iafrati has been nominated to serve as Vice Chair of the Venous Quality Council
Dr. Fedor Lurie has been nominated to serve as Vice Chair of the Venous RAC
Unblinding EVAR Imaging LTFU: Needs to be voted on by each region
Dr. Goodney presented VISION reporting on EVAR Survival, Reintervention, and Surveillance
The GC discussed the impact to moving to virtual regional meetings and ways to make calls more interactive.
Dr. Beck is the new Vice-Chair of the Executive Committee
The PSO will be appointing 2 new at-large members to the PSO Executive Committee

M2S Updates - Fall 2020 - Regional Group Meetings

VQI Technology Updates
Barcode scanning feature for PVI device capture
Released on **2/26/2020**

This new feature can be used to enter device information for all treatment types where the Product Number or DI is required (i.e., excludes plain balloons).

**Hemodialysis Access (HemoDA) minor revision**

Released on **3/26/2020**

Demographics tab:
GFR (eGFR): The GFR numeric field will not allow decimal values. If a decimal value is entered, the value will be automatically rounded to the nearest whole number.
PAD: "None" has been added to options.
HTN: Updated help text and criteria.

History tab:
Central Venous Dialysis Catheter Chest: "None" has been added to options.

Procedure tab:
Intraoperative Target Artery Diameter: Field updates to retire drop-down options and require numeric entry. One decimal value allowed, the value will be automatically rounded to the nearest tenth.
Min/max range values are dependent on the selected Inflow Artery.

**Hemodialysis Access (HemoDA) minor revision (continued)**

Procedure tab:
Intraoperative Target Vein Diameter: Field updates to retire drop-down options and require numeric entry. One decimal value allowed, the value will be automatically rounded to the nearest tenth.
Min/max range values are dependent on the selected Inflow Artery.

Post-Op tab:
Periop Antibiotics: 3 new antibiotic fields have been added (“1st 2nd Gen Cephalosporin”, “Start <1hr Pre-op” and “Stop <24hr Post-op”).

**Across-registry revision Q2 2020**

Released on **4/9/2020**

Hypertension Harmonization

The Hypertension field (in the Demographics tab) was updated to align with current clinical guidelines. Help text and select options are being updated in the CAS, CEA, EVAR, IVC, Infra, LEA, Open AAA, PVI, Supra, TEVAR, VMC, and VUR registries as follows:

New Help Text: “Hypertension = documented in History or recorded blood pressure >= 130/80 (elevation of either systolic or diastolic) on 3 or more occasions. No = no hypertension Yes, controlled = HTN treated with medication, but BP < 130/80 deemed in control; Yes, uncontrolled = HTN not adequately controlled, typically > =130/80 (elevation of either systolic or diastolic) on two occasions.” New select options are: “No”, “Yes, controlled”, or “Yes, uncontrolled.” The former option “Yes (>=140/90 or history) was retired.

**Across-registry revision Q2 2020 (continued)**

Antibiotics Harmonization

Data fields to collect Peri-op antibiotics in the Post-Op tab for the CEA, EVAR, Infra, Open AAA, Supra and TEVAR registries were retired and replaced with new data fields as described below. Peri-op antibiotics were not previously captured in the LEA registry, but the new set of fields were also added to the Post-op section of the amputation registry. Please review new help text associated with these fields. The new subset of data fields are as follows:

“1st 2nd Gen Cephalosporin”
Across-registry revision Q2 2020 (continued)
Free text fields to capture details of “Other” Devices:
The VQI updated several registries to add free text fields, labeled as “Please Specify Other Device(s)”, to capture specific device details when “Other” is selected in device lists.
CEA: to capture “other” Patch Manufacturer in Procedure tab
CAS: to capture “other” EPD Type and “other” Flow Reversal Type in Procedure tab for lesions 1 and 2
EVAR: to capture “other” Anchors Used in Procedure and Re-Tx tab and on Follow-up Re-Tx 1, Re-Tx 2, and Re-Tx 3 tabs
IVC Filter: to capture “other” Device Manufacturer and “other” Filter Type in Procedure tab.
TEVAR: to capture “other” Anchor Type in Aortic Devices and Re-Tx tab and on Follow-up Re-Tx 1 and Re-Tx 2 tabs

TEVAR Revision Q2 2020
Released on 4/29/2020
Procedure Tab:
Sheath size and closure device information will now be captured for right, left or bilateral access. The new fields appear once an “Access” type other than “None” has been selected.
Largest Sheath Size (Fr) - The largest French sheath size used by side. There is a Min/Max range of 16-30. (A table with sheath sizes is included in the help text)
Number of Closure Devices - The number of closure devices used by side (0 to >5).
Closure Device Type – The brand name of the closure device(s) used at the access site. This field will appear if “Number of Closure Devices” is greater than zero.
Specify Other - If “Other” is selected as the “Closure Device Type” this field will appear. Please enter manufacturer and device details by free-text.

TEVAR Revision Q2 2020 (continued)
Post-Op Tab:
Several fields were updated or retired and replaced with new access side-specific data fields and options.
Complications section: These new fields will only display for right and/or left access once an access type other than “None” has been selected for the given side on the procedure tab.
Access Site Hematoma / Pseudoaneurysm – The most extensive treatment of hematoma or pseudoaneurysm by side.
Access Site Occlusion – The most extensive treatment for the occlusion by side.
Access Site Infection – The depth and involvement of infection by side.
The new fields above replaced the following, which were retired:
Puncture Site Hematoma
Access Site Occlusion
Surgical Site infection

TEVAR Revision Q2 2020 (continued)
Post-Op Tab:
Re-intervention section:
Indication (Re-Tx) – The “Access Related” option was retired and new options to indicate “Right access related” and “Left access related” were added.
PVI revision in Q2 2020
Released on 6/29/2020
Demographics Tab:
The “Ambulation” field will no longer appear if the “Bed bound” option is chosen for the “Functional Status” field. Previously the “Ambulation” field displayed and defaulted to “Bedridden”. This change was applied to both the Demographics tab in the procedure form, as well as in the Long Term Follow-up form. The existing select option of “Bedridden” for the “Ambulation” field no longer appears on the form with this new dependency.
Procedure Tab:
Closure Device fields: The following fields were added for both access sites, in both the Basic and Comprehensive PVI forms:
“Number of Closure Devices”, with the options: “1, 2, 3, and >3”.
“Closure Outcome”, with the options: “Closure device successful; Closure device failed; Closure device failed, intervention; and Closure device failed, surgery”.
The “Closure Device Successful” field was retired, and appears in the Data Download files preceded with “R-” (R- Closure Device Successful).
PVI revision in Q2 2020 (continued)
Post-Procedure Tab:
“Hematoma” field: The select options for the existing Hematoma fields (for access site 1 and 2 as applicable) were expanded for greater accuracy.
The following Hematoma options were maintained: “No, Minor, Transfusion and Thrombin injection”. The prior “Surgical Rx” option was re-named “Surgical Re-Tx (intra-op or post-op)” One new option was added: “Interventional Re-Tx (intra-op or post-op)”.
The “Right/Left Amputation Level” fields no longer appear if the “No” option is chosen for the “Amputation During Admission” field. The existing select option of “No” for the “Right and Left Amputation Level” fields no longer appear on the form with this new dependency.
Add PVI Procedure Context variables to Follow-up data download file
Released on 6/29/2020
In response to member feedback, the VQI added two new columns to the PVI Follow-up data download file to identify the specific arteries and sides treated as selected on the procedure form and displayed in the PATHWAYS follow-up form.
The new columns appear before the “Current Patency” fields in the PVI Long Term Follow-up Data Download file. Follow-Up Data Download file additional columns:
“Arteries Treated”
“Side”
The columns appear in groups by field: “Artery Treated 1, Artery Treated 2, Artery Treated 3, Artery Treated 4…, then Side 1, Side 2, Side 3, …, then Current Patency 1, Current Patency 2”, etc.
VSR diameter unit change mm2 -> mm and related help text updates
Released on 7/15/2020
The units associated with the “Minimal Diameter Within Stenosis” and “Minimal Diameter at Reference Location” fields were changed from “mm2” to “mm”.
Hemodialysis Access (HemoDA) revision for tapered graft
Released on 7/29/2020
Three new fields were added to the HDA registry to capture “Tapered Devices”. A new "Tapered Device" field was added to the Procedure tab in the Conduit Details section. If “Yes” is selected for the “Tapered Graft” field, then two new diameter fields display: “Tapered Graft Minimum Diameter” and “Tapered Graft Maximum Diameter”.

**Revised COVID-19 message for Follow-up Mandatory Fields**

Released on **7/29/2020**

The VQI added a temporary message about the impact of COVID-19 on LTFU completion rate calculations. The following message is displayed when submitting a LTFU that is missing any mandatory variable:

“It is important that routine follow up visits may not be possible due to COVID-19 state mandates. Special considerations will be part of our LTFU calculation for 2020, please collect all of the required fields that are possible during this time.”

As a reminder, the VQI allows phone and telehealth appointments to be used for LTFU when Face-to-Face visits are not feasible.

**“Was this helpful?” feature for Help Text**

Released on **7/29/2020**

This new feature is to provide feedback regarding the current help text. For each help text field, users will have the option to indicate if the help text provided was useful or not. This information will help the VQI to identify data fields that may be unclear to members.

The “Was this helpful?” vote up/down button displays in the bottom right corner of the help text box:

- Across-registry revision to add COVID-19 variables
- TEVAR Revision to align with SVS/STS guidelines
- Vascular Ultrasound Registry (VUR) major revision
- Varicose Vein Registry (VVR) revision for New CEAP Clinical Classification
- Venous Stent Registry (VSR) revision for New CEAP Clinical Classification
- Vascular Medicine Consult (VMC) registry revision to add new drug category and update CAD
- VQI PRO collection for PVI

---

**Registry Projects**

- These projects are conducted within the SVS PSO and only non-identifiable data (removal of patient, center and physician information) will be provided to Medtronic/BARD/Cook/Gore or the FDA. Only standard of care practice is being evaluated. For such PSO activities, patient informed consent and Institutional Review Board review are not required.
- Sites must follow their institutional guidelines

0 of the 180 required patients enrolled (5 potential cases in process)
Retrospective enrollment allowed- All eligible cases from December 31, 2018 (protocol FDA approval date)
12 of 40 sites enrolled (11 more in contracting)

This project is conducted within the SVS PSO and only non-identifiable data (removal of patient, center and physician information) will be provided to Medtronic or the FDA. Only standard of care practice is
being evaluated. For such PSO activities, patient informed consent and Institutional Review Board review are not required.

---

**PVI Post-Market Surveillance Projects**

**Medtronic IN.PACT® Admiral® DCB ISR Project**

The Bard® LifeStent® Popliteal Artery Stent Project

**Enrollment Complete**

74 of the 74 required patients enrolled

Retrospective enrollment allowed- All eligible cases from 10/1/2016 (protocol FDA approval date)

29 of 30 sites enrolled

This project is conducted within the SVS PSO and only non-identifiable data (removal of patient, center and physician information) will be provided to Bard or the FDA. Only standard of care practice is being evaluated. For such PSO activities, patient informed consent and Institutional Review Board review are not required.

**Medtronic IN.PACT® Admiral® DCB ISR**

The Medtronic IN.PACT® Admiral® DCB ISR Project Post-market registry surveillance of the clinical use of the Medtronic IN.PACT® Admiral® Paclitaxel-Coated PTA Balloon.

Objective: To assess the long-term safety and performance of the IN.PACT® Admiral® DCB in a U.S. population for the treatment of ISR lesions in the superficial femoral and popliteal arteries.

Patients will be followed at 12, 24 and 36 months

Total reimbursement of **$1,950 per patient** for a patient followed annually for 3 years

1 additional field added:

Check box to indicate that patient is eligible to enroll project based on the inclusion and exclusion criteria.

**Enrollment Complete**

300 of the 300 required patients enrolled

Retrospective enrollment allowed- All eligible cases from December 6, 2016 (protocol FDA approval date)

50 of 50 sites enrolled

This project is conducted within the SVS PSO and only non-identifiable data (removal of patient, center and physician information) will be provided to Medtronic or the FDA. Only standard of care practice is being evaluated. For such PSO activities, patient informed consent and Institutional Review Board review are not required.

**For More Information Contact:**

**Medtronic IN.PACT® Admiral® DCB ISR Project**

Anita Duxbury
MedtronicAdmiralDCB@m2s.com

**The Bard® LifeStent® Popliteal Artery Stent Project**

Charlotte Stirewalt
BardLifeStent@m2s.com
PATHWAYS Support

PATHWAYS Communication
We understand that some members do not always receive mass emails from M2S, due to firewall and spam filter configurations at their centers. In an effort to ensure that all members are aware of important registry updates, we’ve taken the following steps:

Meeting Evaluation
Next Meeting: